CellaVision AB (publ) (STO:CEVI)

Market Cap	3.78B -25.4%
Revenue (ttm)	748.45M +1.5%
Net Income	151.41M +0.8%
EPS	6.35 +0.8%
Shares Out	23.85M
PE Ratio	24.99
Forward PE	22.92
Dividend	2.50 (1.53%)
Ex-Dividend Date	Apr 29, 2026

Volume	30,177
Average Volume	42,168
Open	157.80
Previous Close	158.60
Day's Range	157.80 - 164.40
52-Week Range	139.20 - 208.00
Beta	1.30
RSI	55.66
Earnings Date	Feb 5, 2026

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 231
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CEVI

Financial Performance

In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.